Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
X. Leleu, C. Hulin, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
F. Saj, Y. Nisha, et al.
The effects of omega 3 fatty acids on the serum concentrations of pro inflammatory cytokines and depression status in patients with bipolar disorder: A randomized double-blind controlled clinical trial
H. Eslahi, M. Shakiba, et al.
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCESO1 trial
J. Qin, L. Xue, et al.
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 Neo Trio trial
G. V. Long, M. S. Carlino, et al.
